Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback